NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP.OB), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the appointment of Laura Barrow, Pharm. D. as Vice President, Clinical Operations. In this newly created position, Dr. Barrow will report to President and Chief Executive Officer Gary S. Jacob, Ph.D. and will be responsible for guiding Synergy's clinical programs, including the Phase II/III study for plecanatide, the Company's lead drug candidate.
